youtube_live
Q2 2026 earnings • released • Revenue beat +7.89%
See resultschevron_right
IPN:EPA
Ipsen SA
€153.10
arrow_downward
-8.43%(-14.10) 1D
Aug 3, 5:35:27 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPN...
Open
€164.90
High
€165.20
Low
€153.10
Mkt. cap
13.34B
Avg. vol.
122.89K
Volume
150.98K
P/E ratio
24.79
52-wk high
€173.50
52-wk low
€101.90
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
Open
€164.90
High
€165.20
Low
€153.10
Mkt. cap
13.34B
Avg. vol.
122.89K
Volume
150.98K
P/E ratio
24.79
52-wk high
€173.50
52-wk low
€101.90
EPS
€6.18
Shares outstanding
83.81M
No. of employees
6K
News stories
From sources across the web
TipRanks
·
6 hours ago
Ipsen Reports Share Buybacks on Euronext Paris in Late July 2026
Investing.com Nigeria
·
10 hours ago
Jefferies cuts Ipsen on Camurus competition risk By Investing.com
Profile
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
About Ipsen SA
AI content may include mistakes. Learn more